 Todd Kingdom
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 25 | 2021 | 211 | 3.830 |
Why?
| | Rhinitis | 23 | 2023 | 152 | 3.550 |
Why?
| | Nasal Polyps | 15 | 2017 | 59 | 3.120 |
Why?
| | Endoscopy | 21 | 2024 | 288 | 2.820 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 76 | 1.960 |
Why?
| | Paranasal Sinus Neoplasms | 7 | 2024 | 23 | 1.410 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 9 | 1.100 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 77 | 1.030 |
Why?
| | Nasal Mucosa | 6 | 2019 | 107 | 0.990 |
Why?
| | Skull Base | 6 | 2023 | 46 | 0.920 |
Why?
| | Aspirin | 6 | 2016 | 380 | 0.880 |
Why?
| | Cystic Fibrosis | 7 | 2014 | 1066 | 0.770 |
Why?
| | Orbit | 4 | 2016 | 57 | 0.720 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 338 | 0.600 |
Why?
| | Postoperative Complications | 7 | 2018 | 2477 | 0.600 |
Why?
| | Lipoxygenase | 2 | 2008 | 14 | 0.560 |
Why?
| | Chronic Disease | 19 | 2023 | 1720 | 0.560 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 10 | 0.540 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 3 | 0.500 |
Why?
| | Decompression, Surgical | 2 | 2017 | 96 | 0.490 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 9 | 0.480 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 15 | 0.450 |
Why?
| | Protein Array Analysis | 2 | 2011 | 56 | 0.400 |
Why?
| | Eosinophilia | 3 | 2016 | 204 | 0.380 |
Why?
| | Respiratory System | 1 | 2013 | 155 | 0.380 |
Why?
| | Bronchiectasis | 1 | 2013 | 110 | 0.380 |
Why?
| | Middle Aged | 33 | 2024 | 31136 | 0.380 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 25 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 234 | 0.370 |
Why?
| | Sputum | 1 | 2013 | 302 | 0.360 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 38 | 0.360 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2512 | 0.360 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 119 | 0.360 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 43 | 0.360 |
Why?
| | Immunotherapy | 1 | 2015 | 596 | 0.350 |
Why?
| | Humans | 71 | 2024 | 129625 | 0.340 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 712 | 0.340 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 26 | 0.340 |
Why?
| | Frontal Sinus | 2 | 2007 | 5 | 0.330 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 9 | 0.330 |
Why?
| | Adult | 32 | 2024 | 35599 | 0.320 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 27 | 0.320 |
Why?
| | Surgical Flaps | 3 | 2019 | 136 | 0.320 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 176 | 0.310 |
Why?
| | Retrospective Studies | 22 | 2022 | 14522 | 0.310 |
Why?
| | Mycoses | 3 | 2005 | 72 | 0.310 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.300 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 7 | 0.300 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 72 | 0.300 |
Why?
| | Male | 40 | 2024 | 63670 | 0.290 |
Why?
| | Aged | 24 | 2024 | 22061 | 0.290 |
Why?
| | Treatment Outcome | 14 | 2024 | 10219 | 0.280 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 544 | 0.280 |
Why?
| | Immunoglobulin E | 2 | 2018 | 330 | 0.280 |
Why?
| | Female | 37 | 2024 | 68734 | 0.260 |
Why?
| | Quality of Life | 5 | 2024 | 2688 | 0.260 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 78 | 0.250 |
Why?
| | Nose Neoplasms | 2 | 1996 | 20 | 0.250 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1501 | 0.250 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 17 | 0.240 |
Why?
| | Consensus | 3 | 2021 | 618 | 0.240 |
Why?
| | Osteomyelitis | 1 | 2007 | 121 | 0.230 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 101 | 0.230 |
Why?
| | Streptococcus | 1 | 2004 | 27 | 0.230 |
Why?
| | Hypersensitivity | 3 | 2024 | 249 | 0.230 |
Why?
| | Prednisone | 2 | 2017 | 234 | 0.220 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 69 | 0.220 |
Why?
| | Staphylococcus | 1 | 2004 | 74 | 0.220 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 37 | 0.220 |
Why?
| | Adenoma | 2 | 2018 | 214 | 0.210 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 15 | 0.210 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 25 | 0.210 |
Why?
| | Aged, 80 and over | 11 | 2024 | 7052 | 0.210 |
Why?
| | Bone Diseases | 1 | 2003 | 57 | 0.200 |
Why?
| | Reoperation | 3 | 2019 | 541 | 0.190 |
Why?
| | Adolescent | 14 | 2019 | 20412 | 0.190 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 348 | 0.180 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 28 | 0.180 |
Why?
| | Glucocorticoids | 2 | 2017 | 580 | 0.180 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 5 | 0.180 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 7 | 0.170 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1432 | 0.160 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.160 |
Why?
| | Nasal Septum | 2 | 2020 | 25 | 0.160 |
Why?
| | Sella Turcica | 1 | 2018 | 16 | 0.160 |
Why?
| | Polyethylenes | 1 | 2018 | 14 | 0.150 |
Why?
| | Otolaryngology | 2 | 2011 | 87 | 0.150 |
Why?
| | Parotid Diseases | 1 | 1998 | 5 | 0.150 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 9 | 0.150 |
Why?
| | Up-Regulation | 2 | 2012 | 840 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 10 | 0.150 |
Why?
| | Sclerotherapy | 1 | 1998 | 19 | 0.150 |
Why?
| | Vision Disorders | 2 | 2017 | 135 | 0.150 |
Why?
| | Doxycycline | 1 | 1998 | 59 | 0.150 |
Why?
| | Prospective Studies | 5 | 2024 | 7135 | 0.150 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1685 | 0.150 |
Why?
| | Immunoglobulin D | 1 | 2017 | 29 | 0.140 |
Why?
| | Mucocele | 1 | 2017 | 12 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 135 | 0.140 |
Why?
| | Cysts | 1 | 1998 | 109 | 0.140 |
Why?
| | Melanoma | 2 | 1995 | 730 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4894 | 0.140 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 179 | 0.140 |
Why?
| | Visual Acuity | 2 | 2017 | 327 | 0.130 |
Why?
| | Aspergillosis | 1 | 1996 | 20 | 0.130 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 23 | 0.130 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 23 | 0.130 |
Why?
| | Neuroendoscopy | 1 | 2016 | 19 | 0.130 |
Why?
| | Graves Disease | 1 | 2016 | 35 | 0.120 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 8 | 0.120 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 76 | 0.120 |
Why?
| | Superantigens | 1 | 2015 | 70 | 0.120 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 123 | 0.120 |
Why?
| | Pharynx | 1 | 1995 | 58 | 0.120 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 506 | 0.120 |
Why?
| | Mouth | 1 | 1995 | 84 | 0.120 |
Why?
| | Neck | 3 | 2005 | 95 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 68 | 0.120 |
Why?
| | Young Adult | 8 | 2018 | 12455 | 0.120 |
Why?
| | Biocompatible Materials | 1 | 2018 | 392 | 0.120 |
Why?
| | Dinoprostone | 1 | 2015 | 187 | 0.120 |
Why?
| | Intraoperative Complications | 1 | 2016 | 129 | 0.120 |
Why?
| | Nasal Cavity | 1 | 1995 | 51 | 0.120 |
Why?
| | Meningitis | 1 | 2016 | 79 | 0.120 |
Why?
| | Actinomycosis | 1 | 1994 | 3 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 208 | 0.110 |
Why?
| | Nose Diseases | 1 | 1994 | 12 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 168 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 132 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 373 | 0.110 |
Why?
| | Microbiota | 3 | 2018 | 733 | 0.110 |
Why?
| | Angiofibroma | 1 | 2013 | 5 | 0.110 |
Why?
| | Case-Control Studies | 5 | 2017 | 3378 | 0.110 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 17 | 0.110 |
Why?
| | Pituitary Diseases | 1 | 2013 | 21 | 0.110 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 6 | 0.110 |
Why?
| | Granulocytes | 1 | 2013 | 77 | 0.110 |
Why?
| | HIV Seropositivity | 1 | 1994 | 119 | 0.110 |
Why?
| | Biopsy | 3 | 2017 | 1088 | 0.110 |
Why?
| | Biofilms | 1 | 2015 | 244 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 42 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 460 | 0.100 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 53 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2012 | 116 | 0.100 |
Why?
| | Vital Capacity | 1 | 2013 | 289 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 77 | 0.100 |
Why?
| | Skull Neoplasms | 1 | 2012 | 22 | 0.100 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 106 | 0.100 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 47 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 296 | 0.090 |
Why?
| | Histocytochemistry | 1 | 2011 | 81 | 0.090 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 150 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 958 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 148 | 0.090 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 316 | 0.090 |
Why?
| | Incidence | 2 | 2015 | 2641 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 127 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 399 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3394 | 0.080 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.080 |
Why?
| | Bacteria | 1 | 2016 | 814 | 0.080 |
Why?
| | Caspase 8 | 1 | 2009 | 48 | 0.080 |
Why?
| | Epistaxis | 3 | 2011 | 13 | 0.080 |
Why?
| | Caspase 9 | 1 | 2009 | 56 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2009 | 188 | 0.080 |
Why?
| | Drug Tolerance | 1 | 2009 | 90 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 69 | 0.080 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 17 | 0.080 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 42 | 0.070 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 23 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 834 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1206 | 0.070 |
Why?
| | Maxilla | 1 | 2007 | 33 | 0.070 |
Why?
| | Child | 9 | 2016 | 20884 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 276 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 59 | 0.070 |
Why?
| | Child, Preschool | 5 | 2011 | 10490 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 442 | 0.070 |
Why?
| | Reference Values | 1 | 2008 | 794 | 0.070 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 27 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1705 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 419 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2627 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 819 | 0.060 |
Why?
| | Risk Assessment | 2 | 2013 | 3262 | 0.060 |
Why?
| | Asthma | 2 | 2016 | 2225 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 2730 | 0.050 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 15 | 0.050 |
Why?
| | Fungi | 1 | 2005 | 136 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 3717 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 175 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1071 | 0.050 |
Why?
| | Mouth Diseases | 1 | 2003 | 43 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 348 | 0.050 |
Why?
| | United States | 3 | 2015 | 13871 | 0.050 |
Why?
| | Acute Disease | 2 | 2016 | 979 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 161 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 130 | 0.050 |
Why?
| | Head | 1 | 2003 | 96 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 514 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1947 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2003 | 199 | 0.050 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 29 | 0.040 |
Why?
| | Ecchymosis | 1 | 2000 | 3 | 0.040 |
Why?
| | Mitomycin | 1 | 2020 | 32 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 330 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 99 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 164 | 0.040 |
Why?
| | Orbital Diseases | 1 | 2000 | 28 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1833 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 434 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 35 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 82 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 81 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 4931 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 3 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 9 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 31 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2000 | 235 | 0.040 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.040 |
Why?
| | Larynx | 1 | 1998 | 58 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 148 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 74 | 0.040 |
Why?
| | Syndecan-1 | 1 | 2017 | 28 | 0.040 |
Why?
| | Skin Tests | 1 | 2018 | 100 | 0.040 |
Why?
| | Probiotics | 1 | 2018 | 51 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5415 | 0.030 |
Why?
| | Plasma Cells | 1 | 2017 | 66 | 0.030 |
Why?
| | Mucus | 1 | 2017 | 77 | 0.030 |
Why?
| | Complementary Therapies | 1 | 2018 | 87 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2739 | 0.030 |
Why?
| | Carcinoma | 1 | 1998 | 214 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 234 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1122 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 481 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 57 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 138 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 680 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 276 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 183 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 202 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 49 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 2 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 226 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 3 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 4 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 56 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 13 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 15 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 23 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 29 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 14 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 82 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 47 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 310 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 50 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 5075 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 182 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 57 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 81 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 228 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 127 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1042 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 297 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 385 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 87 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 312 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 205 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 46 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 524 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 329 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 741 | 0.030 |
Why?
| | Perioperative Care | 1 | 2015 | 151 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 139 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 7 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 463 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 524 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1213 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3080 | 0.030 |
Why?
| | Facial Nerve | 1 | 1993 | 34 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 242 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2017 | 851 | 0.030 |
Why?
| | Phospholipase C beta | 1 | 2013 | 30 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.030 |
Why?
| | Transducin | 1 | 2013 | 42 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 165 | 0.030 |
Why?
| | Olfaction Disorders | 1 | 2013 | 60 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 317 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 196 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2013 | 98 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 283 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1465 | 0.020 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 223 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 9786 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 148 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 646 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 314 | 0.020 |
Why?
| | Hematoma | 1 | 2011 | 53 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 93 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 207 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 75 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 324 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 475 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 650 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 147 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1872 | 0.020 |
Why?
| | Animals | 1 | 2012 | 35391 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 387 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1269 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1203 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1687 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1035 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2021 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1282 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 744 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1159 | 0.020 |
Why?
| | Workload | 1 | 2011 | 153 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 477 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 207 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 1986 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 331 | 0.020 |
Why?
| | Pain | 1 | 2013 | 787 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1098 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3968 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1005 | 0.020 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 1993 | 829 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1271 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 998 | 0.010 |
Why?
| | Clinical Competence | 1 | 2011 | 1017 | 0.010 |
Why?
| | Lung | 1 | 1996 | 3938 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 241 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5426 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 591 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 13 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 17 | 0.010 |
Why?
| | Masks | 1 | 2001 | 60 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 27 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 137 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 105 | 0.010 |
Why?
| | Headache | 1 | 2001 | 151 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 15 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1843 | 0.010 |
Why?
| | Infant | 1 | 2011 | 8995 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 321 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1616 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|